Goldman Sachs Initiates Coverage of Corvus Pharmaceuticals with Buy Rating

Shares of Corvus Pharmaceuticals (CRVS) experienced a significant price increase on Friday after Goldman Sachs launched coverage of the biotechnology firm. The investment bank assigned a "Buy" recommendation to the stock, signaling strong confidence in the company's current trajectory. The bullish outlook is centered on the company's lead candidate, soquelitinib. Goldman Sachs analyst Paul Choi characterized the asset as a "pipeline-in-a-product," suggesting that the drug possesses versatile potential across multiple indications, which could significantly expand the company's addressable market. As part of the initiation, Goldman Sachs established a price target of $40 per share. This valuation reflects the perceived upside of the soquelitinib development program and the company's overall pipeline value. The market responded positively to the initiation, with CRVS shares spiking in Friday trading. Investors typically view initiations from top-tier institutions like Goldman Sachs as a validation of a biotech company's scientific approach and commercial viability.